|
Education
Honors and Rewards
Publications
Experience
Research/Multi-Center Studies
Presentations
EDUCATION:
MEDICAL Albany Med, Albany NY, Retina Fellowship July 2002-2003
University of Texas, Houston TX, Retina Fellowship July 2001-2002.
Hahnemann University Hospital, Philadelphia PA, Ophthalmology, July 1998-2001 Lic. #MT-044124-T.
Winthrop University Hospital, Mineola NY, Internal Medicine, completed June 1998 Lic. #210696-1.
SUNY Health Science Center at Syracuse NY, M.D., June 1997.
OPTOMETRY SUNY College of Optometry, New York, NY, O.D., June 1989; Lic. # TOO4994.
COLLEGE Brandeis University, A.B., June 1985.
HONORS AND AWARDS:
MEDICAL
Golden Apple Teaching Award 2003
OPTOMETRY
Beta Sigma Kappa Honor Society
National Deans List
COLLEGE
Cum Laude
Hebrew Language Award
PUBLICATIONS:
Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus Dryja, Andrew M. Wright, Irina Koroleva, Gerard Bruin, Christian Antoni, Zoe Draelos, Michael H. Gold, the Psoriasis Study Group, Patrick Durez, Paul P. Tak, Juan J. Gomez-Reino, the Rheumatoid Arthritis Study Group, C. Stephen Foster, Rosa Y. Kim, C. Michael Samson, Naomi S. Falk, David S. Chu, David Callanan, Quan Dong Nguyen, the Uveitis Study Group, Kristine Rose, Asifa Haider, and Franco Di Padova
Effects of AIN457, a Fully Human Antibody to Interleukin-17a, on Psoriasis, Rheumatoid Arthritis, and Uveitis.
Sci Transl Med 6 Oct 2010 Vol. 2 Issue 52, p. 52ra72
Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N
Adverse Events after Intravitreal Infliximab (Remicade) Retina 30(1): 71-80 (2010)
Beer PM, Wong SJ, Schartman JP, Kulas KE, Hartman CL, Giganti M, Falk NS. Infliximab Stability after Reconstitution, Dilution, and Storage under Refrigeration. Retina 2010 Jan; 30(1): 81-84.
S Itty 1 , S J Bakri 2 , J S Pulido 2 , D C Herman 2 , L J Faia 2 , G T Tufty 3 , S R Bennett 4 and N S Falk
Initial results of QuantiFERON-TB Gold testing in patients with uveitis.
Eye (2009) 23, 904–909
Beer PM , Beer EA, Stepien KE, Stanciu N, Falk NS:
Photographic Evidence of Vitreous Wicks after Intravitreal Injections.
Retina Today, 11-13, Spring 2007
Falk N, Beer PM , Stepien K, Kaw P, Peters GB.
Increased Choroidal Nonperfusion after Combination Therapy with Verteporfin and Intravitreal Triamcinolone Acetonide for Subfoveal Choroidal Neovascularizatin in Age Related Macular Degeneration
Submitted to Retina for publication
Falk N, Beer PM, Peters GB . Role of Intravitreal Triamcinolone Acetonide for the Treatment of Postoperative Endophthalmitis Retina. 26(5):545-548, May/June 2006
Costello P, Bakri SJ, Beer PM, Singh R, Falk N, Peters G, Melendez JA: Vitreous Penetration of Topical Moxifloxacin and Gatifloxacin in Humans. Retina February 2006. 26(2):191-5.
Beer PM , Wong S, Falk N, Hammad A, Khan S, O’Malley M: Vitreous Levels of Unbound Bevacizumab and Unbound Vascular Endothelial Growth Factors in Two Human Subjects. Retina, 2006 Oct; 26(8):871-6
Stepien K, Beer PM, Peters, GB, Falk, NS: Optical Coherence Tomography Findings in the Macula of Patients Undergoing Pneumatic Retinopexy for Rhegmatogenous Retinal Detachment. Invest. Ophthalmol. Vis. Sci. 2005 46:E-abstract 267.
Falk NS, Bakri SJ, Beer PM, Peters GB. Intravitreal Preservative-Free Traimcinolone Acetonide for the treatment of Macular Edema.
Eye . 2005 June; 19(6):686-8.
Beer PM , Bakri SJ, Falk NS, Peters GB. Verteporfin Photodynamic Therapy for Macular Edema Due to Radiation Retinopathy.
To be submitted for publication Ophthalmology
Nickel JA, Bakri SJ, Beer PM, Falk, NS, Peters GB. Verteporfin Photodynamic Therapy for Neovascular Age Related Macular Degeneration Associated with Subretinal Hemorrhage. To be submitted for publication Ophthalmology
Falk NS, Aksionoff EB. The Primary Care Optometric Evaluation of the Traumatic Brain Injury Patient. J Am Optom Assoc. 1992; 63:547-53.
Aksionoff EB, Falk NS. Differential Diagnosis of Perceptual Deficits in Brain Injury Patients. J Am Optom Assoc. 1992; 63:554-8.
Aksionoff EB, Falk NS . Optometric Therapy for Left Brain Injured Patient.
J Am Optom Assoc. 1992; 63:564-8.
EXPERIENCE:
CLINICAL:
Fellowship Director Albany Medical Center
Course Director : Albany Ophthalmology Update 2010
Assistant Professor, Albany Medical Center with surgical privileges at Albany Medical Center, Childs Hospital and Albany Memorial Hospital
July 2003- present.
Practicing in full scope retina and uveitis including management of medical and surgical disease, iodine plaque therapy for choroidal melanoma, Immune modulatory therapy for uveitis plus participation in multi-center clinical trials for macular degeneration, diabetes, venous occlusions, macular edema and uveitis
July 2003-present.
Vitreoretinal Fellow, Albany Medical Center July 2002-June 2003.
Vitreoretinal Fellow, University of Texas, July 2001-June 2002.
Chief Resident, Hahnemann University Hospital, July 2000 – June 2001.
Ophthalmology Resident, Hahnemann University Hospital, July 1998 –June 2001.
Medical Intern, Winthrop University Hospital, July 1997 – June 1998.
Assistant Clinical Professor, SUNY College of Optometry, July 1990 – June 1993.
Staff Optometrist and Clinical Instructor, Veterans Hospital, Northport, NY, June 1990 - June 1993.
Optometric Resident, Veterans Hospital, Northport, NY. Full scope clinical program includes Primary care, Pathology, Low Vision, Contact lenses, Vision Therapy and Head Trauma rehabilitation, July 1989 – June 1990.
RESEARCH/MULTI-CENTER STUDIES:
Sakura 32-007 (Santen)
2011 - present
Dose escalation using intravitreal Sirolimus for noninfectious posterior uveitis
(Phase III)
Principal Investigator
Novartis AIN457 Cohort 6
2011 -present
Intraveous vs Subcutaneous administration of AIN457 for noninfectious
posterior or panuveitis (Double Blinded)
Principal Investigator
Novartis AIN457 Cohort 5
2011-present
Open Label High dose Intravenous AIN457 (30mg/kg) for noninfectious
posterior or Panuveitis
Principal Investigator
INSURE Study
2010
Novartis AIN457 versus placebo for noninfectious intermediate, posterior or
panuveitis (Phase III)
Principal Investigator
Novartis CAIN457A2208 (ENDURE)
2008-present
Assess effects with 2 different doses AIN457 for noninfectious uveitis
(Phase II)
Principal Investigator
Cytokine Concentrations in Primary Retinal Detachment and Proliferative Vitreoretinopathy
2010-1011
Principal Investigator
Ophthotec OPH 1001
2008-2011
Sub-Investigator
Ophthotec OPH 3000
2008-2010
Sub- Investigator
Ophthotec OPH 1000
2008-2009
Sub- Investigator
Retina Research Foundation (NCT00695682)
2008
Intravitreal Infliximab for Diabetic Macular Edema and Choroidal Neovascularization (Phase I Study)
Sub-Investigator
Regeneron [VGFT-06-05]
2007-2010
VEGF trap for Neovascular AMD
Sub-Investigator
RIDE [FVF4168g]
2007-present
Genentech: Lucentis for Diabetic Macular edema
Sub-Investigator
SALVAGE FVF3933
2007-2009
Phase I/II study to evaluate Scotoma Reduction and Limited Visual Acuity in Age Related Macular Degeneration. Patients Treated with Intravitreal Ranibizumab.
Sub-Investigator
AREDS II
2006-present
AREDS 2 The Age- Related Eye Disease Study 2.
Sponsored by the National Eye Institute of Health
Foresee home (Addendum to AREDS II)
2010
Sponsored by National Eye Instittute of Health
Arrxant [B7A-MC-MBCU]
2006-2008
Roboxistaurin for diabetic macular edema
Principal Investigator
Sailor I and Sailor II [FVF3689g]
2005-2007
Phase II, Multi-Center Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization Secondary to Macular Degeneration
Horizon FVF3426g. An Open-Label, Multi-Center
2005-2008
Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) Who have Completed the Treatment Phase of a Genetech-Sponsored Ranibizumab Study.
Pegaptnib Sodium [Macugen]; EOP1010
2005
Compassionate trial
Intravitreal Triamcinalone for Diabetic
2004-2007 Macular Edema Sudy.
Diabetic Retinopathy
Clinical Research Study 1-B, National Eye Institute
Study Protocol Planning Committee
Sub-Investigator
Dexamethasone Posterior Segment Drug Delivery
2004-2006
System (Posurdex) in Treatment of Patients with Macular Edema secondary to Retinal Vein Occlusion. Sub-Investigator
Pegaptanib Sodium [EYE001; Macugen]
2003-2005
versus PDT with Visudyne; EOP 1008
Sub-Investigator
Pilot Laser Photocoagulation for Diabetic
2003-2005
Macular Edema Study. Diabetic Retinopathy
Clinical Research Study 1-A, National Eye Institute
Sub-Investigator.
Efficacy and Safety of rhuFab V2 Compared to
2003-2005
Verteporfin photodynamic Therapy in Subjects with Predominatly Classic Subfoveal Neovascular Age-Related Macular Degeneration
ANCHOR Sub-Investigator
Minimally classic/occult trial of the Antivegf
2003-2005
Antibody Rhufab in the treatment of Neovascular Age related Macular Degeneration
MARINA Sub-Investigator
Prospective and Retrospective Demographic Study of Treatment Regiments for Ocular Trauma,
June 1993 – August 1993.
Laboratory Evaluation of Peroxidase Secretion, Stimulation of Potassium and Phosphate Production in the Rat Lacrimal Gland (Advisor: John Picarelli, PhD.), 1986 – 1988.
Experiments evaluating deposits occurring on soft contact lenses (Advisor: Jerold Rapp, PhD.), 1985 – 1986.
PRESENTATIONS:
Wladis EJ, Falk NS, Iglesias BV, Beer PM, Gosselin EJ. Cytokine Concentrations in Primary Retinal Detachment and Proliferative Vitreoretinopathy
Submitted to AAO
Falk N. Vascular Disease
AOU Conference 2010 (Albany Ophthalmology Update)
Falk N MD
Retisert Implant for Birdshot Chorioretinopathy.
Poster session ASRS 2008
Falk N. Central Retinal Artery Occlusion Treatment and Management.
Ocular Immunology and Uveitis Foundation Physician Education Conference
Boston October 2007
Falk N. Standard of Care Monitoring Macular Degeneration.
Ocular Immunology and Uveitis Foundation Physician Education Conference
Boston October 2007
Falk NS, Beer PM, Hammad AM: Adult Vitelliform Macular Dystrophy Treated with Bevacizumab. 24 th Annual ASRS Meeting, Cannes Retina Festival, Cannes France. September 2006.
Khan S, Beer PM, Falk N, Hammad A, O’Malley M: Six-month Follow-up on 50 Consecutive Patients with Intravitreal Bevacizumab Injections for Neovascular Age Related Macular degeneration. 24 th Annual ASRS Meeting, Cannes Retina Festival, Cannes France. September 2006.
Beer PM , Wong S, Falk N, Hammad A, Khan S, O’Malley M: Vitreous Levels of Unbound Bevacizumab and Unbound Vascular Endothelial Growth Factors in Two Human Subjects. 24 th Annual ASRS Meeting, Cannes Retina Festival, Cannes France. September 2006.
Falk N, Beer PM, Peters GB: Role of Intravitreal triamcinolone Acetonide for the treatment of postoperative endophthalmitis.
Annual meeting of the American Society of Retina Specialists, Montreal,
Canada July 2005
Falk N, Beer PM , Stepien K, Kaw P, Peters GB.
Increased Choroidal Nonperfusion after Combination Therapy with Verteporfin
and Intravitreal Triamcinalone Acetonide for Subfoveal Choroidal
Neovascularization in Age Related Macular Degeneration
Poster session at annual meeting of the American Society of Retina Specialists,
Montreal, Canada July 2005
Stepien K, Beer PM, Peters, GB, Falk, NS: Optical Coherence Tomography Findings in the Macula of Patients Undergoing Pneumatic Retinopexy for Rhegmatogenous Retinal Detachment. Poster Present #267, ARVO, Ft. Lauderdale, FL. May 2005.
Beer PM , Bakri SJ, Falk NS, Peters GB. Verteporfin Photodynamic Therapy for Macular Edema Due to Radiation Retinopathy. 21 st Annual Meeting of the American Society of Retina Specialists, NYC, NY August 20, 2003
Falk NS, Bakri SJ, Beer PM, Peters GB. Intravitreal Preservative-Free Triamcinolone Acetonide for the treatment of Macular Edema. 21 st Annual Meeting of the American Society of Retina Specialists, NYC, NY August 20, 2003
Nickel JA, Bakri SJ, Beer PM, Falk, NS, Peters GB. Verteporfin Photodynamic Therapy for Neovascular Age Related Macular Degeneration Associated with Subretinal Hemorrhage. 21 st Annual Meeting of the American Society of Retina Specialists, NYC, NY August 18, 2003
Falk, N. Anti-VEGF compounds for the Treatment of Macular Degeneration
An Update for Eye Care Providers. Guest Lecturer: The Johns Hopkins
University: Albany Institute of Art. Albany, N.Y., June 18, 2003
Falk, N Developments in Macular Degeneration
Glens Falls Primary Eye Care Conference
Glens Falls, N.Y., May 5, 2003
Falk N Drug Induced Effects on Secretion of the Rat Lacrimal Gland.
American Academy of Optometry; Toronto. Canada; December 1986.
|
